Navigation Links
MS drug shows promise for preventing heart failure
Date:7/16/2013

A drug already approved to treat multiple sclerosis may also hold promise for treating cardiac hypertrophy, or thickening of the cardiac muscle--a disorder that often leads to heart failure, researchers at the University of Illinois at Chicago College of Medicine report.

The findings are published in the July 16 issue of Circulation: Heart Failure.

Cardiac hypertrophy is a slow thickening of the heart muscle that shrinks the interior volume of the heart, forcing the organ to work harder to pump a diminishing volume of blood.

"There comes a day when the heart just can't keep up any more, and it fails," says R. John Solaro, UIC distinguished university professor and head of physiology and biophysics.

Cardiac hypertrophy, which afflicts one in 500 people, can be caused by high blood pressure or inherited through genes that control contraction of the heart.

Solaro and his colleagues believe that if the thickening of the heart muscle could be slowed, or maybe even reversed, heart failure could be prevented.

Solaro and his UIC colleague Yunbo Ke, research assistant professor of physiology and biophysics, were interested in a chemical derived from a fungus used in traditional Chinese medicine as an eternal-youth nostrum. That compound, designated FTY-720, has been developed into a drug to treat multiple sclerosis and is a chemical cousin to the drug most widely used to suppress the immune system and prevent organ rejection in transplant patients.

The substance, Solaro said, "mimics certain lipids in the body that play a role in the development of cardiac hypertrophy."

Using an experimental mouse model of cardiac hypertrophy, Solaro and his team found that FTY-720 significantly reduced heart mass; lessened fibrosis, or stiffening of the heart muscle; and improved overall cardiac function in the mice that received the drug.

The researchers also showed that the drug inhibits expression of several genes involved in cardiac hypertrophy.

"We saw that FTY-720 blocked the activity of a protein we know is involved in causing heart-cell thickening," said Solaro. When that protein is blocked, he said, collagen and other proteins involved in heart-cell thickening are also down-regulated.

Collagen, a fibrous protein found between heart cells, causes the heart muscle to become stiff. Collagen is often overabundant in people with cardiac hypertrophy.

"When the heart muscle is stiff, it actually takes effort to relax the heart and allow blood to flow into the ventricles, so this is another way this disease causes the heart to work harder than it should have to," Solaro said.

"FTY-720 is a potential therapy to treat this disease and prevent heart failure for people where the disease is acquired through high blood pressure, and possibly inherited hypertrophy as well," he said.


'/>"/>

Contact: Sharon Parmet
sparmet@uic.edu
312-413-2695
University of Illinois at Chicago
Source:Eurekalert

Related biology news :

1. Genetic survey of endangered Antarctic blue whales shows surprising diversity
2. University of Houston study shows BP oil spill hurt marshes, but recovery possible
3. Weakness can be an advantage in surviving deadly parasites, a new study shows
4. Study shows unified process of evolution in bacteria and sexual eukaryotes
5. Sexual reproduction brings long-term benefits, study shows
6. UCSB study shows forest insects and diseases arrive in US via imported plants
7. Study shows botanical formula fights prostate cancer
8. Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis
9. Buy coal? New analysis shows purchasing fossil fuel deposits best way to fight climate change
10. Global Surgical Devices Market Growth Driven by Improving Standards of Living and Longer Life Expectancies, Research Shows
11. CU research shows warming climate threatens ecology at mountain research site west of Boulder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 /PRNewswire/ ... leader in dairy research, today announced a new collaboration ... reduce the chances that the global milk supply is ... dairy project, Cornell University has become the newest academic ... Supply Chain, a food safety initiative that includes IBM ...
(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
Breaking Biology News(10 mins):
(Date:9/17/2017)... ... September 17, 2017 , ... ... Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug ... Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents the second ...
(Date:9/14/2017)... , ... September 14, 2017 ... ... the launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary ... translation of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio ...
(Date:9/14/2017)... , ... September 14, 2017 , ... AIM Global, the ... Tracking Systems Inc. has won the 2017 Case Study Competition for AIDC. The ... provide benefits that decrease risk” and push the adoption of automated data collection systems ...
(Date:9/12/2017)... ... 12, 2017 , ... PhysIQ, a Chicago-based company that provides ... monitoring and clinical trial support, earned DPharm Idol 2017 honors at the 7th ... Launched in 2005, PhysIQ leverages artificial intelligence (AI) to empower digital health. The ...
Breaking Biology Technology: